Oxygenta Pharma Closes Trading Window for FY26 Results

Oxygenta Pharmaceutical Limited has announced its trading window will close starting April 1, 2026. This temporary restriction will remain in effect until 48 hours after the company officially declares its audited financial results for the quarter and full fiscal year ending March 31, 2026.

Today's Filing

Oxygenta Pharmaceutical formally notified the Bombay Stock Exchange (BSE) of the upcoming trading window closure. This measure is in line with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will shut from April 1, 2026, until the announcement of the financial results for the fourth quarter and full fiscal year ending March 31, 2026, to prevent insider trading on non-public information.

Standard Compliance

Closing the trading window is a common regulatory step designed to ensure fairness in the market. It stops company insiders, such as directors and key employees, from trading shares while possessing non-public information that could affect stock prices. This practice supports SEBI's goal of protecting investors and maintaining a level playing field.

Company History and Hurdles

Oxygenta Pharmaceutical, previously known as S S Organics Limited, manufactures bulk drugs and active pharmaceutical ingredients (APIs) at its facilities in Telangana. While the company reported strong revenue growth of 178.72% in FY2025, it has also faced significant financial and regulatory challenges. These include net losses for four consecutive quarters and a recent revenue decline. In October 2025, its manufacturing license for key drugs like Vildagliptin and Lacosamide was suspended for seven days due to violations of the Drugs and Cosmetics Act. Earlier, in February 2023, SEBI had fined the company for related party transaction and disclosure issues concerning a loan from ARR Capital. Ongoing net losses also raise concerns about the company's path to profitability.

Who's Affected

Designated employees and their immediate relatives at Oxygenta Pharmaceutical are prohibited from trading the company's securities during this period. The restriction begins on April 1, 2026, and continues until 48 hours after the financial results are officially announced. Trading during this 'blackout period' would be a violation of SEBI regulations.

Industry Practice

Leading Indian pharmaceutical firms like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Divi's Laboratories, Torrent Pharmaceuticals, and Zydus Lifesciences also observe similar trading window closures before announcing financial results. This is a sector-wide standard for market integrity.

What to Watch

Investors should watch for the company's announcement of its Board Meeting date to approve financial results. The released Q4 FY26 and FY26 results will reveal more about the company's financial health and operational performance. Management's commentary on strategies to resolve past regulatory issues and improve profitability will be important.